Tobira appoints Antoun Nabhan
This article was originally published in Scrip
Tobira Therapeutics has appointed Mr Antoun Nabhan as Vice President, Business Development. Reporting to company president and CEO Andrew Hindman, Dr Nabhan will be responsible for the HIV treatment-focused company's strategic transactions and partnering activities, as well as certain operating activities. Mr Nabhan joins Tobira from Onyx Pharmaceuticals, where he held a number of positions in corporate development and strategy, including a key role in the company's acquisition of Proteolix. Prior to Onyx, Mr Nabhan was co-founder, CFO and VP Operations at Presidio Pharmaceuticals, a principal at VC Sagamore Biosciences, and VP Business Development & Finance for Intellico Inc, systems biology company acquired by Genstruct Inc.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.